Core Viewpoint - Tianyao Pharmaceutical Co., Ltd. and its subsidiaries have participated in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected for the continuation of procurement [1][2]. Group 1: Selected Products Information - The company and its subsidiaries are involved in the national centralized procurement for drugs, with results expected to be finalized by the end of March 2026 [1]. - The specific details of the selected drugs will be based on the final data released by the procurement office [1]. Group 2: Impact on the Company - The selected drugs are projected to generate sales revenue of approximately RMB 323 million in 2024, accounting for 10.03% of the company's total revenue for that period [2]. - For the first three quarters of 2025, the expected sales revenue from these drugs is RMB 250 million (unaudited), representing 11.20% of the company's revenue for that timeframe [2]. - The implementation of the procurement results is anticipated to enhance product sales, increase market share, improve brand image, and promote the development of the company's formulation business [2].

Core Viewpoint - The company and its subsidiaries participated in the national organized procurement for drugs, with some products expected to be selected in the follow-up procurement, indicating a strategic move to secure market share in a competitive environment [1] Group 1: Financial Impact - The total expected sales revenue from the selected drugs for the year 2024 is RMB 323 million, accounting for 10.03% of the company's revenue during the same period [1] - The projected sales revenue for the first three quarters of 2025 is RMB 250 million, representing 11.20% of the company's revenue for that timeframe [1]